Hillsdale Investment Management’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Hillsdale Investment Management’s Portfolio BSTC Stock Details BSTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-120	Closed	-$6K	–	688
2019 Q3	$6K	Hold	120	–	–	﹤0.01%	545
2019 Q2	$7K	Sell	120 -10,500	-99%	-$661K	﹤0.01%	514
2019 Q1	$661K	Buy	10,620 +2,620	+33%	+$173K	0.06%	194
2018 Q4	$485K	Buy	+8,000	New	+$478K	0.06%	213
2016 Q1	–	Sell	-5,300	Closed	-$228K	–	569
2015 Q4	$228K	Sell	5,300 -250	-5%	-$12.5K	0.09%	285
2015 Q3	$242K	Sell	5,550 -300	-5%	-$16.2K	0.08%	264
2015 Q2	$302K	Sell	5,850 -4,630	-44%	-$197K	0.09%	251
2015 Q1	$410K	Sell	10,480 -2,000	-16%	-$78.4K	0.11%	164
2014 Q4	$482K	Sell	12,480 -1,000	-7%	-$38.2K	0.12%	133
2014 Q3	$476K	Hold	13,480	–	–	0.15%	102
2014 Q2	$363K	Buy	13,480 +4,000	+42%	+$104K	0.08%	162
2014 Q1	$246K	Buy	+9,480	New	+$227K	0.07%	265

Other funds holding BSTC

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Hillsdale Investment Management's BSTC Position: Q4 2019 in Review

Hillsdale Investment Management sold out of BioSpecifics Technologies Corp. (BSTC) in Q4 2019, closing a stake of 120 shares — an estimated $6K sold.

Hillsdale Investment Management first reported a position in BSTC in Q1 2014 and held it in 12 quarters. The position peaked at $661K in Q1 2019. 112 funds tracked by Wall St. Rank hold BSTC as of Q4 2019.

Hillsdale Investment Management reported no remaining BioSpecifics Technologies Corp. position as of Q4 2019 after selling out during the quarter.
Hillsdale Investment Management sold 120 BioSpecifics Technologies Corp. shares in Q4 2019, an estimated $6K.
Hillsdale Investment Management first reported a position in BioSpecifics Technologies Corp. in Q1 2014 and held it in 12 quarters.
Hillsdale Investment Management's BioSpecifics Technologies Corp. position peaked at $661K in Q1 2019.
112 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q4 2019.

Based on Hillsdale Investment Management's 13F filing for Q4 2019, filed 12 Feb 2020.